Zheng Gan Decoction inhibits diethylnitrosamine-induced hepatocellular carcinoma in rats by activating the Hippo/YAP signaling pathway.
10.12122/j.issn.1673-4254.2025.04.15
- Author:
Tianli SONG
1
;
Yimin WANG
1
;
Tong SUN
2
;
Xu LIU
1
;
Sheng HUANG
1
;
Yun RAN
2
Author Information
1. Department of Medicine, Hubei Minzu University, Enshi 445000, China.
2. Department of Hepatology, Shenzhen Hospital (Longgang) of Beijing University of Chinese Medicine, Shenzhen 518172, China.
- Publication Type:Journal Article
- Keywords:
Hippo/YAP pathway;
Zheng Gan Decoction;
diethylnitrosamine;
hepatocellular carcinoma;
therapeutic mechanism
- MeSH:
Animals;
Drugs, Chinese Herbal/pharmacology*;
Diethylnitrosamine;
Rats, Sprague-Dawley;
Rats;
Signal Transduction/drug effects*;
Protein Serine-Threonine Kinases/metabolism*;
Carcinoma, Hepatocellular/drug therapy*;
YAP-Signaling Proteins;
Liver Neoplasms/drug therapy*;
Hippo Signaling Pathway;
Male;
Liver Neoplasms, Experimental/metabolism*;
Transcription Factors/metabolism*;
Adaptor Proteins, Signal Transducing/metabolism*
- From:
Journal of Southern Medical University
2025;45(4):799-809
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the inhibitory effect of Zheng GanDecoction (ZGF) on tumor progression in a rat model of diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) and explore the possible mechanism.
METHODS:Seventy SD rats were subjected to regular intraperitoneal injections of DEN (50 mg/kg) for 12 weeks to induce HCC tumorigenesis, with another 10 rats receiving saline injections as the normal control. After successful modeling, the rats were randomized into 5 groups (n=10) for daily treatment with distilled water ( model group), Huaier Granules (4 g/kg; positive control group), or ZGF at low, medium, and high doses (2, 4, and 8 g/kg, respectively) via gavage for 17 weeks. Body weight changes of the rats were monitored, and after completion of the treatments, the rats were euthanized for measurement of liver, spleen and thymus indices and morphological and histopathological examinations of the liver tissues using HE staining. The expressions of YAP, p-YAP, MST1, LATS1 and p-LATS1 in the liver tissues were detected using immunohistochemistry and Western blotting.
RESULTS:Compared with the normal control rats, the rat models with DEN-induced HCC exhibited much poorer general condition with a significantly reduced survival rate, increased body weight and liver and spleen indices, and a lowered thymus index. ZGF treatment obviously reduced liver and spleen indices, increased the thymus index, and improved pathologies of the liver tissues of the rat models. Immunohistochemistry and Western blotting showed a dose-dependent reduction of YAP expression and an increment of p-YAP expression in ZGF-treated rats, which also exhibited significantly upregulated hepatic expressions of MST1, LATS1 and p-LATS1.
CONCLUSIONS:ZGF inhibits DEN-induced HCC in rats by activating the Hippo/YAP pathway via upregulating MST1 and LATS1 expression, which promotes YAP phosphorylation and degradation to suppress proliferation and induce apoptosis of the tumor cells.
